Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial
Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
HealthTree University Opens to Help Myeloma Patients Better Direct Their Care
The online portal HealthTree has opened a free…
Ide-cel Application Resubmitted to FDA With Requested Data
Bristol Myers Squibb and Bluebird Bio have resubmitted a biologics…
FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has…
Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has…
First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients
A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s…
